Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.

Treis D, Umapathy G, Fransson S, Guan J, Mendoza-GarcĂ­a P, Siaw JT, Wessman S, Gordon Murkes L, Stenman JJE, Djos A, Elfman LHM, Johnsen JI, Hallberg B, Palmer RH, Martinsson T, Kogner P

JCO Precision Oncology 6 (6) e2100271 [2022-01-00; online 2022-01-28]

Clinical Genomics Gothenburg [Service]

Clinical Genomics Stockholm [Service]

PubMed 35085006

DOI 10.1200/PO.21.00271

Crossref 10.1200/PO.21.00271

pmc: PMC8830523


Publications 8.1.0